| Literature DB >> 35267917 |
Meryem Bakour1, Hassan Laaroussi1, Driss Ousaaid1, Asmae El Ghouizi1, Imane Es-Safi2, Hamza Mechchate2, Badiaa Lyoussi1.
Abstract
The coronavirus disease 2019 (COVID-19) is an epidemic caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). Populations at risk as well as those who can develop serious complications are people with chronic diseases such as diabetes, hypertension, and the elderly. Severe symptoms of SARS-CoV-2 infection are associated with immune failure and dysfunction. The approach of strengthening immunity may be the right choice in order to save lives. This review aimed to provide an overview of current information revealing the importance of bee products in strengthening the immune system against COVID-19. We highlighted the immunomodulatory and the antiviral effects of zinc and polyphenols, which may actively contribute to improving symptoms and preventing complications caused by COVID-19 and can counteract viral infections. Thus, this review will pave the way for conducting advanced experimental research to evaluate zinc and polyphenols-rich bee products to prevent and reduce the severity of COVID-19 symptoms.Entities:
Keywords: COVID-19; SARS-CoV-2; bee products; immunity; natural products; polyphenols; zinc
Mesh:
Substances:
Year: 2022 PMID: 35267917 PMCID: PMC8912813 DOI: 10.3390/nu14050942
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Mechanisms of the immune response against SARS-CoV-2. (A) identification of the spike glycoprotein of SARS-CoV-2, (B) activation of CD4+ helper T lymphocytes, (C) Elimination of the virus and the infected cell. (TLR: Toll-like receptors; NF-κB: nuclear factor-kappa B; TNF: tumor necrosis factor; IL: interleukin; MHCI: major histocompatibility class I; MCHII: major histocompatibility class I; LT4: CD4+ helper T lymphocyte; LT8: CD8+ helper T lymphocytes; TH1: T helper 1; TH2: T helper 2; IFNγ: interferon, LB: lymphocyte B; CTL: cytotoxic T lymphocyte; NK: natural killer; IgA: immunoglobulin A; IgG: immunoglobulin G; IgM: immunoglobulin M).
Figure 2Role of zinc in immunity; (1) blocks the binding of the virus to the receptor; (2) blocks viral replication, (3): Active the thymulin function, (4) inhibit the excessive inflammatory reaction. (SARS-CoV-2: Severe Acute Respiratory Syndrome-Coronavirus 2; ACE2: Angiotensin-Converting Enzyme 2).
The zinc content of bee products (bee bread, bee pollen, propolis, royal jelly) from different countries.
| Bee Products | Country | Collection Period | Content in Zinc | Reference |
|---|---|---|---|---|
| Bee bread | Lithuania | 2018 | From 11.5 to 42.7 mg/kg | [ |
| Morocco | - | 3.31 ± 0.4 mg/kg | [ | |
| Romania | - | From 29.54 to 31.85 mg/kg | [ | |
| Malaysia | - | 60.61 ± 11.81 mg/kg | [ | |
| Turkey | April to September 2018 | From 52.55 to 73.96 mg/kg | [ | |
| Bee pollen | Italy | 2018 | 25.5 mg/kg | [ |
| Denmark | 2018 | 22.3 mg/kg | [ | |
| Sweden | 2018 | 23.3 mg/kg | [ | |
| Slovakia | 2018 | 28.7 mg/kg | [ | |
| Poland | 2018 | 31.7 mg/kg | [ | |
| Lithuania | 2018 | From 20.3 to 27.8 mg/kg | [ | |
| Ukraine | 2018 | From 20.8 to 22.1 mg/kg | [ | |
| Latvia | 2018 | From 23.5 to 24.7 mg/kg | [ | |
| Turkey | (April to September 2018) | From 39.37 to 68 mg/kg | [ | |
| Serbia | (spring and summer of 2011) | From 28.76 to 75.92 mg/kg | [ | |
| Turkey | - | From 25.94 to 49.74 mg/kg | [ | |
| Brazil | August 2005 to April 2006 | From 45.07 to 55.22 mg/kg | [ | |
| Spain | 1993 | From 18.8 to 81.1 mg/kg | [ | |
| Jordan | March to October 2017 | From 25.24 to 77.02 mg/kg | [ | |
| Turkey | - | From 14.832 to 39.037 mg/kg | [ | |
| Slovakia | Spring season 2007 | From 31.9 to 39.9 mg/kg | [ | |
| Poland | June or August 2009. | From 75.2 to 159.3 mg/kg | [ | |
| China | Flower season of 2010 | From 28.25 to 65.30 mg/kg | [ | |
| Turkey | - | From 20.21 to 59.57 mg/kg | [ | |
| Brazil | - | From 39 to 76 mg/kg | [ | |
| Greece | March to October 2018 | From 24 to 90 mg/kg | [ | |
| Propolis | Poland | 2018 | 52.4 mg/kg | [ |
| Lithuania | 2018 | From 31.9 to 102.1 mg/kg | [ | |
| Argentina | - | From 53 to 68 mg/kg | [ | |
| Turkey | - | From 17.60 to 67.60 mg/kg | [ | |
| Poland | - | From 16.88 to 99.68 mg/kg | [ | |
| Spain | - | From 163 to 279 mg/kg | [ | |
| Brazil | - | 113.5 ± 16.9 mg/kg | [ | |
| Argentina | - | From 34.0 to 105.0 mg/kg | [ | |
| Chile | - | From 5.5 to 105.0 mg/kg | [ | |
| Spain | - | From 17.4 to 460.7 mg/kg | [ | |
| Poland | from May to September 2018 | 40.1 ± 2.7 mg/kg | [ | |
| Lithuania | from May to September 2018 | From 31.9 to 102.1 mg/kg | [ | |
| Brazil | from January to March 2011 | From 10 to 50 mg/kg | [ | |
| Serbia | 2013 | From 19.2 to 241 mg/kg | [ | |
| Greece | Between spring 2013 and August 2014 | From 30.7 to 383.8 mg/kg | [ | |
| Honey | Morocco | Summer of 2015 and 2016 | From 1.09 to 4.02 mg/kg | [ |
| Lithuania | 2018 | From 1.08 to 5.15 mg/kg | [ | |
| Italy | 2018 | 2.03 mg/kg | [ | |
| Greece | 2018 | 2.18 mg/kg | [ | |
| Serbia | 2016 | From 0.78 to 1.84 mg/kg | [ | |
| New Zealand | Autumn 2007 | From 0.2 to 2.46 mg/kg | [ | |
| Malaysia | From January 2013 to March 2014 | From 1.25 to 4.56 mg/kg | [ | |
| Brazil | From July 2007 to March 2009 | From 0.07 to 1.85 mg/kg | [ | |
| Palestine | Between April and August 2009 | From 2.06 to 8.36 mg/kg | [ | |
| Malaysia | between July 2010 and August 2011 | From 4.70 to 173.77 mg/kg | [ | |
| China | - | From 0.59 to 22.85 mg/kg | [ | |
| Poland | 2004–2005 | From 0.30 to 8.40 mg/kg | [ | |
| Egypt | Cotton season 2011 | From 1.63 to 2.57 mg/kg | [ | |
| Ethiopia | - | From 0.370 to 1.124 mg/kg | [ | |
| Kenya | - | From 0.05 to 0.35 mg/kg | [ | |
| Cuba | - | From 0.20 to 1.71 mg/kg | [ | |
| Mexico | -- | From 1.51 to 6.80 mg/kg | [ | |
| Royal jelly | Germany, | 2017 | From 18.1 to 19.7 mg/kg | [ |
| Lithuania | 2018 | 24.1 mg/kg | [ | |
| France and china | May, June, and July 2001 | From 19.4 to 24.8 mg/kg | [ | |
| China | Between September and October 2014 | From 17.56 to 24.91 mg/kg | [ | |
| China | - | From 20 to 26 mg/kg | [ |
Zinc as adjuvant therapy in the management of COVID-19: clinical trials.
| Clinical Trial Study | Dose/Route and Treatment Duration | Drugs/Dietary Supplement | Number of Participants/Age/Sex | ClinicalTrials.gov Identifier/Phase |
|---|---|---|---|---|
| Efficacy of subcutaneous ivermectin with or without zinc in COVID-19 patients | 20 mg/day of zinc sulfate, orally 3 times a day | Ivermectin and zinc | 180/18 years and older/males and females | NCT04472585/Phase II |
| A randomized, | 220 mg/day of zinc Sulfate, once daily, orally for 5 days | Zinc sulfate | 300/18 years and older/males and females | NCT04621461/Phase IV |
| A study of quintuple therapy to treat COVID-19 infection Hydroxychloroquine | No available data | Hydroxychloroquine, Azithromycin/Vitamin C, vitamin D and zinc | 600/18 years and older/both sexes | NCT04334512/Phase II |
| Zinc versus multivitamin micronutrient supplementation to support immune health in the setting of COVID-19 pandemic: a randomized study | 11 mg/day of zinc, orally during 3 months | Vitamin E, vitamin C, zinc, copper and beta-carotene | 2700/between 18 to 90 years/both sexes | NCT04551339/Complited |
| Anti-inflammatory/antioxidant oral nutrition supplementation in COVID-19 | Oraldietary | Supplement enriched with zinc, selenium vitamin A | 30/between 18 to 65 years/both sexes | NCT04323228/Phase III |
| The study of quadruple therapy zinc, quercetin, bromelain, and vitamin C on the clinical outcomes of patients infected with COVID-19 | 50 mg/day, orally during 10 days | Quercetin, bromelain, vitamin C and Zinc | 60/18 years and older adult)/males and females | NCT04468139/Phase IV |
| A preventive treatment for migrant workers at high-risk of COVID-19 | 80 mg/day of zinc tablet, once a day for 42 days | Hydroxychloroquine, Ivermectin, povidone-iodine/vitamin C, and zinc | 5000/between 21 to 60 years/both sexes | NCT04446104/Phase III |
| Comparative study of hydroxychloroquine associated with zinc and ivermectin in COVID-19 prophylaxis | 20 mg/day of zinc twice a day for 45 days | Hydroxychloroquine and Ivermectin/zinc | 400/between 18 to 70 years/both sexes | NCT04384458/not available |
| A study of hydroxychloroquine and zinc in the prevention of COVID-19 infection in military healthcare workers | 15 mg/day of zinc sulfate, orally during 2 months | Hydroxychloroquine/zinc | 660/between 18 to 65 years/both sexes | NCT04377646/Phase III |
| International ALLIANCE study of therapies to prevent progression of COVID-19 | 30 mg/day of zinc citrate, orally for 14 days | Hydroxychloroquine and Azithromycin/Zinc Citrate, Vitamin C, vitamin D3, and vitamin B12 | 200/18 years and older/both sexes | NCT04395768/Phase II |
| Community-based intervention trial to compare theimpact of preventive and therapeutic zinc supplementation programs amoung young children | 20 mg/day of zinc, orally for 10 days during episodes of diarrhea | Zinc | 7680/18 years and older/both sexes | NCT00944359/not available |
| Hydroxychloroquine and zinc with either azithromycin or doxycycline for treatment of COVID-19 in outpatient setting | 220 mg of zinc sulfate once a day, orally for 5 days | Hydroxychloroquine, Azithromycin, Doxycycline/zinc | 750/30 years and older/males and females | NCT04370782/Phase IV |
| Trial of combination therapy to treat COVID-19 infection | No available data | Ivermectin, doxycycline Hcl/zinc, vitamin C, and vitamin D | 31/between 18 to 75 years/males and females | NCT04482686/Pahse I |
| Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine in treatment of COVID-19? | No available data | Chloroquine/zinc | 200/adults/males and females | NCT04447534/Phase III |
Phenolic compounds in bee products.
| Bee Products | Country | Collection Period | Content in Individual Polyphenols (mg/kg) | Reference |
|---|---|---|---|---|
| Propolis | Morocco | From the first of May to mid-June 2018 | Catechin (9.6 ± 1.17); vanilic acid (5.6 ± 0.90); | [ |
| Italy | Not mentioned | Chrysin (781.5 ± 80.1); Apigenin (132.1 ± 21.6); Acacetin (1133.3 ± 256.2); Tectochrysin (130.9 ± 21.6); Pinocembrin (769.4 ± 77.9); Pinostrobin (575.6 ± 48.6); Sakuranetin (152.9 ± 20.6); Galangin (70.4 ± 11.8); Kaempferide (39.8 ± 3.6); Quercetin (153.5 ± 18.6); Prenyl caffeate (33.3 ± 2.6); Benzyl caffeate (527.1 ± 61.8); caffeic acid phenylethyl ester (1745.2 ± 245.2) | [ | |
| China | Not mentioned | Chrysin (2333.0 ± 350.0); Apigenin (178.6 ± 34.8); Acacetin (1578.0 ± 141.9); Tectochrysin (238.3 ± 24.6); Pinocembrin (2087.5 ± 347.0); Sakuranetin (146.0 ± 18.4); Galangin (1400.3 ± 126.6); Kaempferide (38.8 ± 5.0); Quercetin (70.9 ± 9.7); Prenyl caffeate (56.2 ± 6.0); Benzyl caffeate (1477.0 ± 116.6); caffeic acid phenylethyl ester (2525.0 ± 199.3) | [ | |
| Argentina | Not mentioned | Chrysin (2347.6 ± 215.7); Apigenin (336.9 ± 41.7); Acacetin (831.5 ± 16.0); Tectochrysin (224.7 ± 29.0); Pinocembrin (3362.5 ± 418.8); Sakuranetin (27.5 ± 4.1); Galangin (2253.7 ± 294.4); Kaempferide (38.1 ± 4.6); Prenyl caffeate (29.7 ± 4.2); Benzyl caffeate (1180.1 ± 200.8); caffeic acid phenylethyl ester (1111.6 ± 125.6) | [ | |
| Ukraine | Not mentioned | Chrysin (922.0 ± 111.2); Apigenin (177.4 ± 15.2); Acacetin (658.9 ± 67.0); Tectochrysin (153.6 ± 18.7); Pinocembrin (1196.5 ± 91.9); Pinostrobin (1479.3 ± 303.5); Sakuranetin (2184.0 ± 196.1); Galangin (952.9 ± 106.8); Kaempferide (91.9 ± 13.7); Quercetin (28.9 ± 4.1); Prenyl caffeate (53.9 ± 6.1); Benzyl caffeate (465.1 ± 31.9); caffeic acid phenylethyl ester (1145.9 ± 98.6) | [ | |
| Macedonia | Not mentioned | Chrysin (1649.8 ± 177.5); Apigenin (236.4 ± 34.1); Acacetin (1343.0 ± 200.2); Tectochrysin (987.1 ± 104.0); Pinocembrin (2112.0 ± 184.5); Pinostrobin (3816.0 ± 397.1); Sakuranetin (2203.4 ± 269.0); Galangin (903.9 ± 88.2); Kaempferide (43.2 ± 7.0); Quercetin (94.8 ± 10.3); Benzyl caffeate (400.6 ± 62.6); caffeic acid phenylethyl ester (1263.1 ± 212.6) | [ | |
| Morocco | May 2018 | Ferrulic acid (40.60 ± 0.6); o-Coumaric acid (35.47 ± 0.2); Chlorogenic acid (25.31 ± 0.0); Rosmarinic acid (222.02 ± 6.2); Vanilic acid (10.58 ± 0.1); Ellagic acid (37.94 ± 0.1); Catechin (18.83 ± 0.1); Naringin (290.19 ± 0.2); Hesperidin (271.77 ± 0.0); Quercetin (14.78 ± 0.2); Apigenin (50.37 ± 0.8); Kaempferol (26.48 ± 1.2); Rutin (34.37 ± 1.3); Resveratrol (86.25 ± 0.2) | [ | |
| Morocco | July 2018 | Vanillic acid (8.61 ± 0.30); o-Coumaric acid (11.44 ± 4.63); Ferulic acid (18.84 ± 0.21); Ellagic acid (28.55 ± 1.99); Naringin (35.78 ± 4.10); Hesperidin (417.18 ± 50.0); Apigenin (38.39 ± 2.60); Resveratrol (116.89 ± 12.7); Rosmarinic acid (470.35 ± 52.00); Rutin (12.40 ± 0.42); Chlorogenic acid (16.11 ± 0.12); Quercetin (12.02 ± 0.13); Kaempferol (21.90 ± 1.60) | [ | |
| Bee bread | Morocco | Not mentioned | Kaempferol- | [ |
| Romania | spring of 2020 | kaempferol (31.25), myricetin (3.15), luteolin (1.17), rosmarinic acid (0.23), Caffeic acid (0.10), | [ | |
| North-East European countries | 2015 | Gallic Acid (300); Caffeic Acid (between 700 to 6400); Catechin (between 900 and 52,100); Clorogenic acid (between 800 to 1400); | [ | |
| South-West European countries | 2015 | Caffeic acid (between 4600 to 6600); Catechin (between 1700 and 6300); Clorogenic acid (between 400 to 7300); | [ | |
| South | 2015 | Gallic acid (300); Catechin (between 20800 to 34,100); Clorogenic acid (200); | [ | |
| Bee pollen | Morocco | May 2018 | Ferrulic acid (17.17 ± 0.4); cinnamic acid (46.01 ± 7.8); o-Coumaric acid (27.10 ± 1.9); Rosmarinic acid (127.30 ± 6.2); Gallic acid (32.54 ± 2.2); Vanilic acid (6.13 ± 0.1); Ellagic acid (13.02 ± 0.0); Naringin (113.71 ± 6.8); Hesperidin (15.63 ± 6.8); Quercetin (48.12 ± 2.8); Apigenin (162.85 ± 17.7); Rutin (95.36 ± 3.7); Resveratrol (44.00 ± 0.4) | [ |
| Turkey | 2007–2008 | Gallic acid (from 9.46 to 18.59); Protocatechuic acid (from 4.73 to 19.77); | [ | |
| Chile | Not mentioned | Feluric acid (7.75 ± 0.39); Syringic acid (7.92 ± 0.40); | [ | |
| Honey | Morocco | July 2018 | Vanillic acid (2.90 ± 0.01); Ferulic acid (8.35 ± 0.01); Ellagic acid (5.09 ± 0.02); Cinnamic acid (4.25 ± 0.01); Chlorogenic acid (7.06 ± 0.11); Gallic acid (30.06 ± 0.23) | [ |
| Chile | Not mentioned | Chlorogenic acid+caffeic acid (19.67 ± 0.98); Sinapic acid (from 17.58 to 23.86); Feluric acid (from 4.21 to 16.29); Syringic acid (4.73 ± 0.24); Luteolin (from 8.16 to 11.55); Cinnamic acid (3.00 ± 0.15); Quercetin (5.88 ± 0.29); Kaempherol (from 17.00 to 37.00) | [ | |
| Hong Kong, Spain, Italy, Korea, China, Canada, Brazil, New Zealand, and Germany | Not mentioned | gallic acid (from 20 to 66); protocatechuic acid (from 7.1 to 63); 2,3,4-trihydroxybenzoic acid (from 11 to 28); protocatechualdehyde (from 7 to 63); | [ | |
| Morocco | Not mentioned | Methyl syringate (from 277.93 to 443.89); Epicatechin (from 30.67 to 179.29); Syringic acid (from 25.16 to 105.86); Catechin (from 14.56 to 66.13); 4-coumaric acid (from 5.13 to 49.43); Gallic acid (from 0.00 to 34.40); Quercetin (from 7.53 to 42.77); Apigenin (from 1.25 to 33.38); Luteolin (from 0.00 to 22.08); Kaempferol (from 5.24 to 19.64); Naringenin (from 0.00 to 42.41); Formononetin (from 0.87 to 17.88); Genistein (from 0.00 to 24.00); 3-coumaric acid (from 2.40 to 8.66); Daidzein + Pelargonidin (from 1.84 to 8.16); 2-coumaric acid (from 0.45 to 8.17); Biochanin A (from 0.86 to 4.10); Cyanidin (from 0.00 to 2.30) | [ |
Figure 3Possible mechanism of action of phenolic compounds in the management of COVID-19.
Efficacy of flavonoids in vitro and in silico against SARS-CoV-2.
| Type of the Study | Compounds Used | Key Results | Reference |
|---|---|---|---|
| In silico | glyasperin A and broussoflavonol F | Both compounds have favorable interaction profiles with SARS-CoV-2 main protease (PDB ID 6Y2F) catalytic sites (His41 and Cys145) with binding similarities of 75% and 63%, respectively, compared to potent inhibitors. | [ |
| In silico | caffeic acid phenethyl ester | Caffeic acid phenethyl ester can bind to the substrate-binding pocket of SARS-CoV-2 Mprowith efficacy and binding energies equivalent to an already claimed N3 protease inhibitor | [ |
| In silico | apigenin, chrysin, fisetin, galangin, hesperitin, luteolin, morin, naringin, quercetin, rutin, qercetin, kaempferol, | All the flavonoids studied have a high binding affinity with the active site of the spike protein of SARS-CoV-2 | [ |
| In silico | 3-phenyllactic acid, caffeic acid phenethyl ester, caffeic acid, chrysin, galangin, lumichrome | caffeic acid phenethyl ester, caffeic acid, chrysin, galanginhave a strong binding affinity with a good glide score and may inhibit the COVID-19 Mpro and replication of the virus. | [ |
| In silico | luteolin, apigenin, tangeritin, kaempferol, quercetin, myricetin, fisetin, hesperitin, naringenin, eriodicytol, luquiritin, genistein, daidzein, callophyllolide, cyanidin, delphenidin, malvidin, pelargonidin, peonidzin, arbutin, pheloretin, chalconaringenin | cyanidin may suppress rdrp by binding at asp761 catalytic residue and halting the viral replication process. | [ |
| In silico and in vitro | a total of 220 phenolic compounds were tested in the study | In silico and in vitro results indicate that hypericin, rutin, and cyanidin-3- | [ |
| In silico | rutin, caffeic acid phenethyl ester, quercetin, kaempferol, | Docking studies revealed that Rutin and | [ |